Antitumor activity of a nitrosourea derivative, CNUA, on murine tumors.
The antitumor activity of a new derivative of nitrosourea, 3-[3-(2-chloroethyl)-3-nitrosoureido]-3-deoxy-D-allose (CNUA), against murine tumors was studied. CNUA showed significant antitumor activity against L1210 leukemia, Lewis lung carcinoma, B-16 melanoma and autochthonous lung tumor induced by 1-ethyl-1-nitrosourea. The effect of CNUA, chlorozotocin, and ACNU on the peripheral white blood cell count (WBC) in normal CDF1 mice was examined. The lowest WBC count occurred 3 days after administration at the therapeutic dose level and the decreased value returned to the normal level 7-14 days following administration of CNUA and chlorozotocin. CNUA also exerted a depressive action on both humoral and cell-mediated immune response to sheep red blood cells determined by the serum hemagglutinin titer, plaque-forming cells in the spleen, and delayed-type hypersensitivity reaction, while the suppression was almost the same or less than that obtained with chlorozotocin when compared at the dose resulting in similar antitumor activity. These findings suggest that the antitumor activity of CNUA was not at all inferior to those of other nitrosoureas. The bone marrow toxicity was moderate and did not last long.